Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL27588918 | 0.95 | AGTR1 (0.70) | AGTR1 | |
| SCHEMBL7890351 | 0.87 | AGTR1 (0.60) | AGTR1 | |
| SCHEMBL9386649 | 0.87 | AGTR1 (0.65) | AGTR1 | |
| Water SCHEMBL9029753 | 0.86 | AGTR1 (0.64) | AGTR1 | |
| SCHEMBL8437135 | 0.85 | AGTR1 (0.66) | AGTR1 | |
| SCHEMBL583 | 0.85 | AGTR1 (0.53) | AGTR1 | |
| SCHEMBL8438879 | 0.84 | AGTR1 (0.68) | AGTR1 | |
| SCHEMBL8434040 | 0.84 | AGTR1 (0.65) | AGTR1 | |
| SCHEMBL9386724 | 0.84 | AGTR1 (0.65) | AGTR1 | |
| Water SCHEMBL8433835 | 0.83 | AGTR1 (0.67) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051401-B1 | PROCESS FOR THE PRODUCTION OF FORMYLIMIDAZOLES | LONZA AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-6469178-B2 | CONVERSION OF HYDROXYMETHYL IMIDAZOLES TO FORMYLIMIDAZOLES IN THE PRESENCE OF A PEROXIDE USING A NOBLE METAL CATALYST. | LONZA AG (CH) | 2002-10-22 | — | — | US | disclosed |
| US-20020045760-A1 | PROCEDURE FOR PRODUCING FORMYLIMIDAZOLES | LONZA AG | 2002-04-18 | — | — | US | disclosed |
| US-20010014743-A1 | Procedure for producing formylimidazoles | LONZA AG | 2001-08-16 | — | — | US | disclosed |
| CN-1285824-A | Process for preparing formylimidazoles | LONZA AG (CH) | 2001-02-28 | — | — | CN | disclosed |
| EP-1051401-A1 | PROCESS FOR THE PRODUCTION OF FORMYLIMIDAZOLES | LONZA AG (CH) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999025696-A1 | PROCESS FOR THE PRODUCTION OF FORMYLIMIDAZOLES | LONZA AG (CH) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014743-A1 | Procedure for producing formylimidazoles | HMBS, PPOX, MAOB | AGTR1 4842/4885 |
| US-20020045760-A1 | PROCEDURE FOR PRODUCING FORMYLIMIDAZOLES | HMBS, PPOX, MAOB | AGTR1 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.